RAPID MICRO BIOSYSTEMS, INC.(RPID)— Stock Profile, AI Score & Financials

Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

RAPID MICRO BIOSYSTEMS, INC. (RPID) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores RPID at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,619 of 2,962 stocks — the bottom half of the AI-ranked universe. RPID scores in the top quartile across institutional flow (92.1), revenue growth (82.6). Areas of concern include balance sheet strength (1.8) and free cash flow (6.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RAPID MICRO BIOSYSTEMS, INC. reports quarterly revenue of $8.1M, net income of $-12.9M, free cash flow of $-12.9M. Top institutional holders of RPID by reported 13-F value include Bain Capital Life Sciences Investors, ARMISTICE CAPITAL, ABG-WTT Global Life Science Capital Partners GP Ltd, based on the most recent SEC filings. RPID trades on the Nasdaq exchange and files with the SEC under CIK 1380106. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RPID daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RAPID MICRO BIOSYSTEMS, INC. directly from SEC EDGAR.

AI Quality Score

26.5/100

AI Rank

#2,619

Revenue

$8.1M

Net Income

$-12.9M

Free Cash Flow

$-12.9M

RPID key financials by period

RAPID MICRO BIOSYSTEMS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$33.6M$-47.1M-141.1%
FY 202410-K$28.1M$-46.9M-178.0%
FY 202310-K$22.5M$-52.5M
FY 202210-K$17.1M$-60.8M
FY 202110-K$23.2M$-73.5M
FY 202010-K$16.1M$-37.1M-190.0%

Institutions holding RPID

Institutional investors reporting a position in RAPID MICRO BIOSYSTEMS, INC. on SEC Form 13F.
InstitutionSharesValueReported
Bain Capital Life Sciences Investors8,434,560$14.6M2026-06-30
ARMISTICE CAPITAL3,328,000$5.8M2026-06-30
ABG-WTT Global Life Science Capital Partners GP Ltd1,848,296$3.2M2026-06-30
VANGUARD CAPITAL MANAGEMENT982,034$1.7M2026-06-30
Evernest Financial Advisors506,000$875.4K2026-06-30
ADVENT INTERNATIONAL, L.P.379,794$657.0K2026-06-30
ESSEX INVESTMENT MANAGEMENT362,696$627.5K2026-06-30
MILLENNIUM MANAGEMENT236,599$409.3K2026-06-30
GEODE CAPITAL MANAGEMENT228,041$394.7K2026-06-30
RENAISSANCE TECHNOLOGIES212,101$366.9K2026-06-30
RPID

RAPID MICRO BIOSYSTEMS, INC.

RPID
NasdaqSmall CapTechnology

13F Pro Quality Score

26.5/100

Rank #2,619 of 2,962 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

82.6/100

Profitability

6.4/100

Balance Sheet

1.8/100

Earnings Quality

7.7/100

Free Cash Flow

6.2/100

Institutional Flow

92.1/100

Revenue Scale

6.4/100

Dilution Risk

14.4/100

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$8.05M

Net Income

Q2 2026
EDGAR

$-12.92M

EPS (Diluted)

Q2 2026
EDGAR

$-0.27

Free Cash Flow

Q2 2026
EDGAR

$-12.93M

Debt/Equity

Q2 2026
EDGAR

1.08

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…